Investors Alerted to Join Lawsuit Against Indivior PLC Over Financial Losses

Investors who have incurred financial losses with Indivior PLC, a pharmaceutical company specialized in developing treatments for opioid dependence, are being called to participate in a class action lawsuit. The claim is being facilitated by the law firm Levi & Korsinsky, LLP, and focuses on shareholders who have invested in the company's stock held under the NASDAQ ticker INDV. The announcement was made on September 5, 2024, through a GLOBE NEWSWIRE release, urging shareholders who felt aggrieved by potential securities fraud to come forward.

Background on Indivior PLC

Indivior PLC, operating out of North Chesterfield, Virginia, is primarily engaged in creating buprenorphine-based prescription medications aimed at treating opioid addiction and associated disorders. Despite its crucial role in addressing the opioid crisis, concerns have arisen regarding the company's practices and their impact on investor assets.

Details on the Class Action

The class action lawsuit represents a collective effort by shareholders to seek reparations for financial damages allegedly caused by Indivior's actions. Affected investors are encouraged to contact Levi & Korsinsky to acquire more information about the lawsuit and to learn about potential avenues for compensation. It serves as a reminder of the importance of corporate transparency and responsibility towards shareholders.

Indivior, ClassAction, Investors